Over the past year, many AbbVie Inc. insiders sold a significant stake in the company which may have piqued investors' ...
AbbVie Inc. (NYSE:ABBV – Get Free Report) shares hit a new 52-week high on Friday . The company traded as high as $207.42 and ...
We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...
A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Under the leadership of Rob Michael, AbbVie continues to make tremendous progress in developing its immunology and ...
Hosted on MSN1d
CHMP recommends AbbVie’s Rinvoq be approved for adult GCAThe treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...
JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...
Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...
AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with ...
AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...
AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion recommending the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback